4DMedical Limited has announced a significant step in its international growth strategy, signing a binding agreement to acquire Vienna-based medical imaging AI company contextflow GmbH. The deal gives the ASX-listed respiratory imaging specialist an immediate commercial and clinical base in Europe, adding to its established operations in North America, Australia and New Zealand. For 4DMedical, the acquisition is designed to accelerate market entry in a region where demand for advanced lung diagnostics is being shaped by ageing populations, respiratory disease burden and expanding screening programs.
4DMedical Moves Into Europe Through contextflow Deal
Under the agreement, 4DMedical will acquire 100% of contextflow from existing equity holders, including founders, employees and external investors. The company said contextflow brings an experienced Vienna-based team, regulatory and clinical infrastructure, a growing customer base and products already deployed under Europe’s medical device framework. Markus Holzer, contextflow’s chief executive, is expected to lead 4DMedical’s European operations as General Manager of Europe, maintaining regional continuity while supporting expansion.
A Strategic Fit Across Lung Screening and Imaging
contextflow develops AI-supported clinical decision software for chest CT analysis, with a focus on lung cancer, interstitial lung disease and COPD. Its CE-marked ADVANCE Chest CT offering is intended to assist radiologists in detection, triage and workflow efficiency, complementing 4DMedical’s functional lung imaging portfolio, including CT:VQ™. The combination is expected to broaden 4DMedical’s reach across the lung health pathway, from early disease detection to functional assessment and longer-term monitoring.
Transaction Structure and Expected Completion
The upfront consideration comprises €11.42 million, or about A$18.56 million, in cash and 56,235 ordinary shares, with the cash component to be funded from existing reserves. Subject to performance milestones and shareholder approval, sellers may also receive up to 2.59 million zero exercise price options over two years, linked to revenue targets, European CT:VQ™ integration, FDA clearance for ADVANCE Chest CT and pharmaceutical contracts. 4DMedical will also retain €19.0 million, or about A$30.8 million, in accumulated tax losses, which may be used to offset future taxable income generated by the Austrian business.
Commercial and Clinical Implications
The acquisition gives 4DMedical a ready-made European platform rather than requiring it to build a regional presence from scratch. contextflow’s commercial base includes insurance reimbursement contracts in Germany for lung cancer screening, creating potential near-term opportunities and a channel for introducing CT:VQ™ across the region. The company also expects the expanded clinical network to strengthen its relationships with key opinion leaders, pharmaceutical companies and research partners conducting multinational studies.
Completion is expected in or around late July 2026, subject to regulatory approval from Austria’s Federal Ministry of Economy, Energy and Tourism and customary conditions. 4DMedical said the transaction materially advances its ambition to become a global leader in advanced lung analysis software while adding structural detection capabilities to its functional imaging strengths. If integration proceeds as planned, the contextflow acquisition could provide 4DMedical with a scalable foothold in Europe and a broader offering for clinicians managing respiratory disease.